| ViraferonPeg (peginterferon-α-2b) / Merck (MSD) |
NCT00087568: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin |
|
|
| Completed | 4 | 57 | US | Ribavirin, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/06 | 03/06 | | |
NCT00087607: Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC). |
|
|
| Completed | 4 | 385 | US | Ribavirin, Copegus, Peginterferon alfa-2b (PEG-Intron), Rebetol, Peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/06 | 04/06 | | |
NCT00279565 / 2005-000240-82: Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED) |
|
|
| Terminated | 4 | 128 | Europe | buprenorphine, methadone, pegylated interferon alfa-2b plus ribavirin | Indivior Inc., AESCA Pharma GmbH | Hepatitis C, Chronic | 02/07 | 02/07 | | |
NCT00277862: Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4 |
|
|
| Completed | 4 | 280 | RoW | Pegylated IFN- alpha 2b, PEG-IFN alpha-2b, PEG-Intron™, Ribavirin, Rebetol, Virin, Ribavrin | Ain Shams University, Schering-Plough, Fulbright, Tempus Labs, International Society for Infectious Diseases | Hepatitis C | 03/07 | 04/07 | | |
NCT00351871: Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy |
|
|
| Completed | 4 | 400 | US | PEG-Intron Plus REBETOL | Louisiana State University Health Sciences Center in New Orleans, Schering-Plough | Chronic Hepatitis C | 11/07 | 11/07 | | |
NCT00087646: REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy |
|
|
| Completed | 4 | 948 | US, Canada, Europe, RoW | Ribavirin, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 05/08 | 05/08 | | |
NCT00202839: Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) |
|
|
| Completed | 4 | 160 | NA | PegIntron (peginterferon alfa-2b; SCH 54031), peginterferon alfa-2b; SCH 54031, Ribavirin, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 07/08 | 07/08 | | |
NCT00687544: Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED) |
|
|
| Terminated | 4 | 11 | NA | Peginterferon alfa-2b (SCH 054031), PegIntron, Ribavirin (SCH 018908), Rebetol | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepacivirus, HIV Infections | 09/08 | 09/08 | | |
NCT00502099: Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4 |
|
|
| Completed | 4 | 217 | RoW | Pegylated interferon alpha 2a, Pegaesys, Ribavirin, Viracure, Pegylated interferon alpha 2 b plus ribavirin, PEG-Interon | Amr Hafez, Ain Shams University | Hepatitis C | 05/09 | 05/09 | | |
NCT00493805 / 2006-000757-21: Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303) |
|
|
| Terminated | 4 | 59 | NA | Combination of pegylated interferon alfa-2b and ribavirin, (a) SCH 54031, PEG-Intron, (b) SCH 18908, Rebetol | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Insulin Resistance | 10/09 | 10/09 | | |
NCT01195181: Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. |
|
|
| Completed | 4 | 506 | Europe | peginterferon plus ribavirin, Pegasys, PegIntron, Copegus, Rebetol | Azienda Ospedaliera di Padova, Regione Veneto, University of Padova | Hepatitis C Virus, Chronic Liver Disease, Viral Hepatitis, Therapeutic Uses, Antiviral Agents | 12/09 | 08/10 | | |
NCT00207363: Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC |
|
|
| Completed | 4 | 610 | US | Ribavirin, Peg interferon alfa 2b, Peg interferon alfa 2b (Peg Intron), induction therapy, Peg Intron (peginterferon alfa 2b | Brooke Army Medical Center, T.R.U.E. Research Foundation | Hepatitis C | 01/10 | 01/10 | | |
NCT00132210: Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients |
|
|
| Completed | 4 | 200 | Europe | pegylated interferon, Pegasys, PegIntron, Copegus, Rebetol | University Hospital, Bonn | Hepatitis C, HIV Infections | 06/10 | 06/10 | | |
NCT00686777: Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED) |
|
|
| Completed | 4 | 75 | NA | Pegylated Interferon alfa-2b, SCH 54031, Ribavirin, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 12/10 | 12/10 | | |
| Terminated | 4 | 99 | Europe | pegylated interferon alpha-2b, PegIntron, Ribavirin, Rebetol, pegylated Interferon alpha-2b | HepNet Study House, German Liverfoundation, Hannover Medical School | Hepatitis C, Chronic | 08/13 | 08/13 | | |
NCT01405027: Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy |
|
|
| Completed | 4 | 197 | US | Educational Intervention, Peg-Intron, Pegasys, Victrelis, Pegylated interferon alfa 2B, Pegylated interferon alfa 2A, Boceprevir, Ribavirin, Patient education and management skills training | Chronic Liver Disease Foundation, SCRI Development Innovations, LLC, Merck Sharp & Dohme LLC | Chronic Hepatitis C, Genotype 1 | 07/14 | 07/14 | | |
|
| Completed | 4 | 93 | US | Pegylated Interferon alfa-2b, Pegintron, Simeprevir, Olysio, Ribavirin, Ribavirin Ribasphere Ribapak, Sofosbuvir, Sovaldi | Center For Hepatitis C, Atlanta, GA | Chronic Hepatitis C | 12/14 | 04/15 | | |
NCT01285050: Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds |
|
|
| Completed | 4 | 20 | US | Antiretroviral therapy (ART), raltegravir, Isentress, Emtricitabine and tenofovir disoproxil fumarate, Truvada | Johns Hopkins University, National Institute on Drug Abuse (NIDA) | HIV Infection, Hepatitis C | 04/15 | 04/15 | | |
| Completed | 4 | 82 | Europe, RoW | PegIFN alfa-2b, Pegintron | Foundation for Liver Research | Chronic Hepatitis B | 08/15 | 08/15 | | |
NCT01770223 / 2012-002771-33: A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113) |
|
|
| Withdrawn | 4 | 0 | NA | boceprevir, SCH 503034, PegIFN-2b, Peginterferon alfa-2b, PegIntron, SCH 054031, RBV, Ribavirin, Rebetol | Merck Sharp & Dohme LLC | Hepatitis C | 12/15 | 12/15 | | |
NCT01838772: HCV Treatment in HIV Co-Infected Patients in Asia |
|
|
| Completed | 4 | 188 | RoW | Pegylated-Interferon and Ribavirin, PegIntron, Rebetol | amfAR, The Foundation for AIDS Research, Kirby Institute | Hepatitis C, HIV | 06/16 | 09/16 | | |
NCT01727271: A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384) |
|
|
| Withdrawn | 4 | 0 | RoW | Tenofovir, Truvada, Pegylated interferon alpha-2b, SCH 054031, MK-4031 | Merck Sharp & Dohme LLC | Hepatitis B | 08/17 | 08/17 | | |
